Welcome to our dedicated page for Nature’S Sun SEC filings (Ticker: NATR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for Nature’s Sunshine Products, Inc. (NASDAQ: NATR), a natural health and wellness company that manufactures and distributes herbal, nutritional and personal care products. As a registrant on the Nasdaq Capital Market, Nature’s Sunshine files periodic and current reports that describe its operations, financial condition, risk factors and material corporate events.
Through this filings feed, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for Asia, Europe, North America and Latin America & Other, along with discussions of gross margins, selling, general and administrative expenses, adjusted EBITDA and the impact of foreign currency. These reports also incorporate detailed risk factor disclosures related to government regulation, direct selling, independent consultants, product liability, supply chain disruptions, cybersecurity, data privacy and tax matters.
Nature’s Sunshine also uses current reports on Form 8-K to announce material events. Recent 8-K filings have covered quarterly financial results, executive leadership changes such as the appointment of a new Chief Executive Officer, secondary public offerings by a selling stockholder, share repurchase agreements, and share purchase agreements to acquire interests in joint ventures in Hong Kong and Shanghai. These filings often reference non-GAAP measures and include reconciliations in attached exhibits.
Investors can also monitor registration statements and prospectus supplements related to offerings of common stock, as well as agreements tied to concurrent share repurchases. Where applicable, Form 4 and other insider transaction reports provide additional insight into trading activity by directors and officers.
On Stock Titan, AI-powered tools summarize lengthy filings, highlight key changes from prior periods and surface important items such as segment performance, capital allocation decisions, material contracts and governance updates. Real-time ingestion from EDGAR helps ensure that new NATR filings, including 10-Ks, 10-Qs, 8-Ks and ownership reports, are available quickly with plain-language explanations to support deeper research into Nature’s Sunshine’s regulatory and financial disclosures.
Nature’s Sunshine Products, Inc. (Nasdaq: NATR) has filed a 424(b)(5) prospectus supplement covering the resale of 2,854,607 existing shares of common stock owned by the sole selling stockholder, Fosun Pharma USA Inc. The shares will be offered to the public at $12.00 per share, a 20.5 % discount to the last reported Nasdaq price of $15.10 on 24 June 2025.
The transaction is a secondary offering; therefore NATR will not receive any of the estimated $32.7 million in net proceeds (after $1.54 million in underwriting discounts) that will go directly to the selling stockholder.
Share-repurchase overlay. Under a previously announced authorization, the company has the option—but not the obligation—to repurchase up to $15 million of the offered shares at the public offering price through the underwriter, D.A. Davidson & Co. Management expects any buy-back to be funded with cash on hand and draws on its credit facility. The filing emphasizes that no minimum quantity is guaranteed, so there is no assurance the company will purchase any shares.
Key terms
- Offering size: 2,854,607 shares
- Public offering price: $12.00 per share
- Gross proceeds to selling stockholder: $34,255,284
- Underwriting discount: $0.54 per share (total $1,541,488)
- Net proceeds to selling stockholder (before expenses): $32,713,796
- Expected settlement: on or about 27 June 2025 via DTC book-entry
Strategic context. The filing does not involve the issuance of new shares, so there is no dilution to existing shareholders. However, the discounted pricing and block size could create near-term market supply pressure. Management’s discretionary buy-back authority may partially offset this pressure and signals confidence, but the lack of a binding commitment leaves uncertainty.
Form 144 Notice of Proposed Sale filed for Nature's Sunshine Products (NASDAQ: NATR) indicates a planned sale of 2,000 common shares with an aggregate market value of $29,801.88. The securities were acquired on May 2, 2025, through restricted share grants and compensation.
The filing reveals significant recent selling activity by Richard D Moss and the Richard D Moss Revocable Trust over the past 3 months, totaling 37,734 shares sold between May 9, 2025, and June 23, 2025, with gross proceeds of approximately $545,500. Notable transactions include:
- Largest single sale: 10,000 shares on May 9, 2025 ($137,426.61)
- Most recent sale: 3,000 shares on June 23, 2025 ($44,155.45)
- Average sale price: approximately $14.46 per share
The proposed sale will be executed through Wells Fargo Clearing Services, with an approximate sale date of June 25, 2025. The company currently has 18,350,801 shares outstanding.